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Abstract: Neuroendocrine serum markers released from prostate cancers have been proposed for
monitoring disease and predicting survival. However, neuroendocrine differentiation (NED) in
various tissue compartments of metastatic prostate cancer is poorly described and its correlation
with specific tumor features is unclear. NED was determined by Chromogranin A expression on
immunostains from a tissue microarray of 119 nodal positive, hormone treatment-naïve prostate
cancer patients who underwent radical prostatectomy and extended lymphadenectomy. NED in the
primary cancer and in the metastases was correlated with tumor features and survival. The mean
percentage of NED cells increased significantly (p < 0.001) from normal prostate glands (0.4%), to
primary prostate cancer (1.0%) and nodal metastases (2.6%). In primary tumors and nodal metastases,
tumor areas with higher Gleason patterns tended to display a higher NED, although no significance
was reached. The same was observed in patients with a larger primary tumor volume and higher total
size and number of metastases. NED neither in the primary tumors nor in the metastases predicted
outcome significantly. Our data suggest that (a) increasing levels of neuroendocrine serum markers
in the course of prostate cancer might primarily derive from a poorly differentiated metastatic tumor
component; and (b) NED in conventional hormone-naïve prostate cancers is not significantly linked
to adverse tumor features.
Keywords: prostate cancer; lymph node metastases; neuroendocrine; chromogranin A; prognosis
1. Introduction
The current World Health Organization (WHO) classification of prostate neoplasms with
neuroendocrine (NE) differentiation (NED) comprises of: (1) adenocarcinomas with NED;
(2) well-differentiated NE tumors (carcinoid); (3) small-cell NE carcinomas; and (4) large cell NE
carcinomas [1]. While the last three entities are exceedingly rare, the first occurs frequently. In 10–100%
of the conventional adenocarcinomas, NED can be demonstrated immunohistochemically in the form
of scattered NE cancer cells, depending on the number of slides evaluated and the number of antibodies
used [1].
NE cells in prostate cancer most likely emerge from the secretory prostate cancer cells by
trans-differentiation [2–4]. Each NE cell may store a single, or a mix of neuropeptides in cytoplasmic
granules, including Chromogranin A, the most frequently detected and most intensely studied NE
product in prostate tissue [5], serotonin, somatostatin and bombesin [6]. The exact biological function
of neuropeptides in prostate cancer is largely unknown; however, data indicate that they may stimulate
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growth, differentiation and secretory processes [5,7]. While small and large cell NE carcinomas are
particularly aggressive [8], the prognostic significance of NE cells in conventional adenocarcinomas of
the prostate is still controversial [4,9,10]. Importantly, neuropeptides released from the NE prostate
cancer cells may appear in the circulation [6]. These serum markers have recently attracted considerable
attention for their ability to monitor disease [6,11] and predict survival [12,13]. NE serum markers have
been suggested as beneficial surrogates for tumor burden [6] and mirror prostate cancer progression
when raising. In line with this, serum levels of Chromogranin A are significantly higher in metastatic
compared to non-metastatic prostate cancers [14]. However, despite this interest in NE serum markers,
little is known about the distribution of their source, which are the NE tumor cells, in the various
growth patterns and in the metastases of prostate cancer. In this study, we more accurately describe
the extent of NED in the different tissue compartments of metastasizing prostate cancer, and determine
its correlations with different tumor features and survival.
2. Results
2.1. Patient Characteristics and Expression of Chromogranin A in Benign Prostate, Primary Tumors and
Lymph Node Metastases Considering the Gleason Patterns
The patient, prostatectomy and lymphadenectomy characteristics are specified in Table 1. A higher
proportion of 92% of primary tumors displayed any positivity for Chromogranin A compared to lymph
node metastases with a positive expression in 77%. When the density of NE cancer cells was recorded,
a progressive and significant increase in expression from non-neoplastic prostate glands (0.4% mean of
Chromogranin A positive cells) to primary tumors (1.0%) and lymph node metastases (2.6%; p < 0.001)
was noted for Chromogranin A (Figure 1A).
A tendency for higher Chromogranin A expression in less-differentiated tumor areas (reflected by
a higher Gleason pattern (GP)) was observed in the primary tumors (GP3: 0.8% mean of Chromogranin
A positive cells; GP4: 1.0%; GP5: 1.4%; p > 0.05) and in the nodal metastases (GP3: 0.0%; GP4: 1.8%;
GP5: 7.8%; P = NE), but no statistical significance was reached (Figure 1B).
Table 1. Characteristics of 119 nodal positive prostate cancer patients.
Patient Data (n = 119)
Age (median, range) at surgery (years) 65 (45–75)
Follow-up (median, range) (years) 5.9 (0.1–15.2)
Patients with biochemical failure at last follow-up (n) 103
Patients dead of disease at last follow-up (n) 33
Patients dead at last follow-up (n) 40
Prostatectomy Data
pT2 (n) 14
pT3a (n) 55
pT3b (n) 50
Prostate cancer volume (median, range) (cm3) 12.6 (0.66–127)
Gleason score 6 (n) 12
Gleason score 7 (n) 63
Gleason score 8 (n) 21
Gleason score 9 (n) 23
Lymphadenectomy Data
Evaluated nodes per patient (median, range) (n) 22 (9–68)
Positive nodes per patient (median, range) (n) 2 (1–24)
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Figure 1. Mean density of Chromogranin A positive cells is significantly different between normal prostate 
glands, primary prostate cancer and matched lymph node metastases ((A) p < 0.001). The difference 
between the Gleason patterns is not significant ((B) p > 0.05). 
2.2. Correlations of Chromogranin A Expression in Primary Tumors and Lymph Node Metastases with  
Clinico-Pathological Tumor Characteristics and Survival 
Primary tumors with Chromogranin A expression were larger (mean 21.5 ± 24.9 cm3 versus 18.0 ± 15.4 
cm3; p = 0.821) and the tumor burden of a Chromogranin A positive metastasizing component was higher 
for mean total size and number of metastases (36.4 ± 49.4 mm versus 19.4 ± 31.7 mm; p = 0.458 and 5.3 ± 6.9 
versus 3.3 ± 3.4; p = 0.279) (Table 2); however, these differences were not statistically significant. 
Chromogranin A expression in primary tumors or lymph node metastases was not associated with 
categorical tumor characteristics as stage of the primary tumor. In univariate analysis, Chromogranin A 
expression in primary tumors or lymph node metastases did not significantly predict biochemical 
recurrence-free, cancer-specific, or overall survival (Figure 2). Only the total size of metastases 
independently predicted all three endpoints in a multivariate analysis (Table 3). 
Table 2. Tumor features according to Chromogranin A expression. 
CgA  
Expression 
Parameters of the Primary Tumor
(Mean ± SD) 
Parameters of Nodal Metastases
(Mean ± SD) 
 Age p Tumor volume (cm3) p Total size (mm) p Total number p 
Primary Tumor 
CgA negative 64.4 ± 6.1 0.978 18.0 ± 15.4 0.821 19.6 ± 34.8 0.989 3.3 ± 3.8 0.813 
CgA positive 64.3 ± 5.8  21.5 ± 24.9  17.2 ± 24.4  3.0 ± 3.3  
Nodal Metastases 
CgA negative 64.3 ± 5.9 0.027 19.1 ± 19.5 0.819 19.4 ± 31.7 0.458 3.3 ± 3.4 0.279 
CgA positive 59.3 ± 6.3  18.9 ± 13.7  36.4 ± 49.4  5.3 ± 6.9  
Figure 1. Mean density of Chromogranin A positive cells is significantly different between normal
prostate glands, primary prostate cancer and matched lymph node metastases ((A) p < 0.001).
The difference between the Gleason patterns is not significant ((B) p > 0.05).
2.2. Correlations of Chromogranin A Expression in Primary Tumors and Lymph Node Metastases with
Clinico-Pathological Tumor Characteristics and Survival
Primary tumors with Chromogranin A expression were larger (mean 21.5 ± 24.9 cm3 versus
18.0 ± 15.4 cm3; p = 0.821) and the tumor burden of a Chromogranin A positive metastasizing
component was higher for mean total size and number of metastases (36.4 ± 49.4 mm versus
19.4 ± 31.7 mm; p = 0.458 and 5.3 ± 6.9 versus 3.3± 3.4; p = 0.279) (Table 2); however, these differences
were not statistically significant. Chromogranin A expression in primary tumors or lymph node
metastases was not associated with categorical tumor characteristics as stage of the primary tumor.
In univariate analysis, Chromogranin A expression in primary tumors or lymph node metastases did
not significantly predict biochemical recurrence-free, cancer-specific, or overall survival (Figure 2).
Only the total size of metastases independently predicted all three endpoints in a multivariate analysis
(Table 3).
Table 2. Tumor features according to Chromogranin A expression.
CgA
Expression
Parameters of the Primary Tumor
(Mean± SD)
Parameters of Nodal Metastases
(Mean± SD)
Age p Tumor volume (cm3) p Total size (mm) p Total number p
Primary Tumor
CgA negative 64.4 ± 6.1 0.978 18.0 ± 15.4 0.821 19.6 ± 34.8 0.989 3.3 ± 3.8 0.813
CgA positive 64.3 ± 5.8 21.5 ± 24.9 17.2 24.4 3.0 ± 3.
Nodal Metastases
CgA negative 64.3 ± 5.9 0.027 19.1 ± 19.5 0.819 19.4 ± 31.7 0.458 3.3 ± 3.4 0.279
CgA positive 59.3 ± 6.3 18.9 ± 13.7 36.4 ± 49.4 5.3 ± 6.9
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Figure 2. Chromogranin A expression in primary tumors and metastases is not significantly correlated with 
outcome. 
  
Figure 2. Chromogranin A expression in primary tumors and metastases is not significantly correlated
with outcome.
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Table 3. Multivariate analyses for the prognostic impact of Chromogranin A (CgA) expression in
primary prostate cancer (upper half) and in lymph node metastases (lower half), after adjustment
for total size of metastases and Gleason score of primary tumor: Only nodal tumor burden predicts
survival independently. HR, hazard ratio; and CI, confidence interval.
Parameter Cut-Off
Overall Survival Disease-Specific Survival Recurrence-Free Survival
HR (95% CI) p HR (95% CI) p HR (95% CI) p
CgA in Primary
Tumor
Positive 1.0 0.132 1.0 0.241 1.0 0.66
Negative 1.65 (0.9–3.1) 1.54 (0.8–3.1) 1.1 (0.7–1.7)
Metastases size
<7.5 mm 1.0 <0.001 1.0 0.002 1.0 0.036
≥7.5 mm 4.34 (2.0–9.6) 4.12 (1.7–10.0) 1.58 (1.1–2.4)
Gleason score
6 to 8 1.0 0.571 1.0 0.375 1.0 0.074
9 to 10 1.23 (0.6–2.5) 1.41 (0.7–3.0) 1.57 (1.0–2.6)
CgA in Nodal
Metastases
Positive 1.0 0.571 1.0 0.5 1.0 0.327
Negative 0.73 (0.2–2.2) 0.65 (0.2–2.8) 0.69 (0.3–1.4)
Metastases size
<7.5 mm 1.0 <0.001 1.0 0.003 1.0 0.063
≥7.5 mm 5.3 (2.0–14.1) 6.44 (1.9–22.1) 1.58 (1.0–2.5)
Gleason score
6 to 8 1.0 0.365 1.0 1.88 1.0 0.082
9 to 10 1.43 (0.7–3.1) 1.75 (0.8–4.0) 1.62 (0.9–2.8)
3. Discussion
Only a few studies on prostate cancers have evaluated NED in metastatic tissues from lymph
nodes and various other organs with immunohistochemistry [15–20]. Reported incidences for bone
metastases were 19% [18] and 52% [16], those for lymph node metastases 12% [19], 37.5% [17] and
46% [16]. A wide range in the extent of NED in metastases was also noted in an autopsy series
by Roudier et al. [20], specifically between patients, and also between different metastases of a
single patient. In our series, NED in lymph node metastases was present in 77% of the patients.
The metastases had a lower prevalence for NED positivity compared to the primary tumors, which
showed NE differentiation in 92%. This decrease was consistent with the only two series on NED in
surgically treated nodal positive prostate cancer reported by Bostwick et al. [17] and Quek et al. [19].
However, when considering not only the presence or absence of NED, but also the density of positive
cells in primary tumors and metastases, we noticed a significant increase in NED in metastases when
compared to primary tumors. Furthermore, NED increased in higher Gleason patterns in the primary
tumors, and was even more striking in the metastases where tumor growths of Gleason pattern
5 showed the highest levels of NED among all evaluated cancer components. Our findings were
consistent with reports on a positive correlation of the extent of NED and the Gleason score in primary
tumors [21,22]. Together with the previously described correlation of Chromogranin A expression by
the tumor tissue with its serum level [23], our data might suggest that elevated NE serum markers in
metastatic prostate cancer [14] may primarily reflect the metastatic, frequently poorly differentiated
tumor burden [24–26].
The presence of NED in our prostate cancer patients showed a tendency for association with
adverse tumor characteristics. Patients with detected NED in primary tumors had larger tumors, and
those with NED present in metastases had a greater nodal tumor burden, indicated by more metastases
and greater total diameter of metastases when compared with patients without NED. Consistent
with our data, Quek et al. [19] reported the association of high NED with an advanced tumor stage.
Furthermore, NED in the primary tumors of our patients translated into long-term survival. After
five years, the curves for disease-specific and overall survival segregate clearly indicated a poorer
outcome for patients with NED when compared to those without NED. However, this was not
significant, most likely due to the size of our cohort. Contrarily, survival curves based on NED in
lymph node metastases intersected repeatedly. Only two other studies have evaluated NED in nodal
positive prostate cancer patients treated by radical prostatectomy and bilateral lymphadenectomy.
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NED detected by Chromogranin A was not a risk factor in the study by Bostwick et al. [17], neither
in the primary tumors nor in the metastases, whereas Queck et al. [19] reported significantly poorer
median recurrence-free and overall survival for patients with high NED in the primary tumor and
metastases, respectively, when compared to patients with low NED. However, survival curves were
not presented in the latter study and other outcome measures were not significantly different.
Previous studies on NED in prostate cancer tissues assessed expression on large sections (for
comprehensive review of the literature see Table 3 in Bostwick et al. [17]) and cancers were categorized
as negative (absence of NE cells), or positive (presence of NE cells). While it was generally noticed that
NED in prostate cancer is a very focal, dispersed phenomenon, reported incidences for NED varied
between 24 and 98.5% [17]. This wide range was attributed to differences between the cohorts, sample
types, types and extent of fixation, the antibodies used in determining the presence of malignant
NE cells, variance in interpretation and, most importantly, a sampling error related to the focal and
unequal distribution of NE cells in most tumors [27]. It is evident that the amount of tumor tissue
evaluated may impact on reported prevalence in cases of only focally expressed biomarkers like NED.
We determined NED in primary tumors and metastases by tissue microarray (TMA). This technology
has also been considered to be useful for these focally expressed biomarkers in prostate cancer by a
study comparing the expression of NE markers on whole tissue sections to a TMA [28]. Investigating
these focally expressed biomarkers on large sections may have also been problematic as tissue slides
from primary prostate cancer generally contain much greater amounts of tumor tissue than the usually
scarce metastatic tissue that makes the comparison of incidences difficult. However, the use of a TMA
certainly remains a limiting factor in our study. Finally, for a delicate biomarker like NED in prostate
cancer, the size of the cohort may play a major role in detecting significant correlations between tumor
features and survival. Our cohort was comparably large for surgically treated nodal positive prostate
cancer and therefore allowed detection of a significant increase in NED in nodal metastases and trends
between biomarker expression levels, tumor features and survival. However, it may have been too
small to demonstrate these trends as significant.
4. Materials and Methods
4.1. Patients
In total, 119 consecutive prostate cancer patients without demonstrable metastases (physical
and radiological examination), but with nodal metastases upon histological investigation of the
lymphadenectomy specimens were studied. All patients had undergone standardized surgery at the
Department of Urology, University of Bern between 1989 and 2006 with bilateral extended pelvic
lymphadenectomy and radical prostatectomy as a single procedure. Follow-up was performed
prospectively. Neoadjuvant therapy was not implemented and no adjuvant treatment, especially
androgen deprivation, was suggested before symptomatic disease progression.
4.2. Surgical Technique of Lymphadenectomy
A bilateral pelvic lymphadenectomy was performed in all patients as previously described [29].
Summarized, lymph nodes were dissected along the external iliac vein down to the deep circumflex
iliac vein and femoral canal, up to the bifurcation of the common iliac artery and the obturator fossa.
Thereafter, the lymphatic tissue along the medial and lateral aspect of the internal iliac artery and
vein was excised. Three tissue samples from each side were submitted separately for pathological
examination. Frozen sections were not carried out.
4.3. Pathology
All specimens were processed at the Institute of Pathology, University of Bern [24,30].
The prostatectomies were completely embedded as described in references [24,30]. The following
microscopic tumor characteristics were noted: type, Gleason score [31], tertiary Gleason pattern,
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tumor stage, and the percentage of prostate tissue area on the sections occupied by the tumor.
NE tumors/carcinomas of the prostate were excluded. Tumor volume was estimated by multiplying
the percentage of the specimen involved by cancer by the prostate volume.
The fatty tissue of lymphadenectomy specimens was dissolved in aceton after formalin fixation
and all lymph nodes were entirely embedded. One section per paraffin block was stained with
hematoxylin and eosin. The length and width of the metastatic deposits were measured. A Gleason
score (primary and secondary pattern) and a tertiary Gleason pattern (if present), were determined
based on the entire metastatic tissue.
All Gleason patterns present in the primary tumors and lymph node metastases were accurately
marked for subsequent TMA construction. Staging was completed according to the 8th edition of the
International Union Against Cancer (UICC) TNM Classification [32].
4.4. Tissue Microarray
For TMA construction, one 0.6 mm tissue core of benign prostatic tissue (peripheral zone) and
every Gleason pattern present in primary tumors and matched lymph node metastases was retrieved
from the paraffin blocks. The TMA contains overall 403 prostate tissue samples, 119 normal prostate
tissues and 284 primary cancers (mean per patient, 3.3; range, 2–4; including 101, 112 and 71 samples
from Gleason patterns 3, 4 and 5, respectively) and 167 lymph node metastases (mean per patient, 1.4;
range, 1–3; including 35, 103 and 29 samples from Gleason patterns 3, 4 and 5, respectively). In the vast
majority of primary tumors, all Gleason patterns sampled were present in the index tumor. Additional
tissue from separate tumor foci was included only rarely, when a Gleason pattern not present in the
index tumor was detected here. Although sampling from the primary tumor was more extensive, the
relative tumor amount in the TMA was larger from the metastases due to their smaller volume.
4.5. Immunohistochemistry
Freshly cut TMA sections were pre-treated by steam with target retrieval solution, pH 9 (Dako,
Glostrup, Denmark). For Chromogranin A detection, a monoclonal mouse antibody cocktail (clone
LK2H10 + PHE5; Bicarta; Hamburg, Germany) was used at 1:500 antibody dilution. Bound primary
antibodies were detected using the Envision Plus system (Dako, Glostrup, Denmark). Chromogranin
A was expressed in the cytoplasm of the prostate cancer cells (Figure 3). The percentage of positive
neoplastic cells was determined for every tissue sample.
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Figure 3. No Chromogranin A expression in (A) primary prostate cancer; and (B) high Chromogranin
A expression in a lymph node metastasis.
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4.6. Statistical Analysis
Chromogranin A expression in normal prostate, primary tumors and lymph node metastases
was evaluated using the Wilcoxon Signed Rank test and the Friedman test for differences between
Gleason pattern 3, 4 and 5 within primary carcinomas and nodal metastases. Chromogranin A
expression was compared with normally distributed quantitative and categorical tumor attributes
using Wilcoxon Signed Rank test and χ-Square test, respectively. Suitable cut-off values for positive
(more than 0 positive cells) and negative (0 positive cells) Chromogranin A expression in primary
tumors and lymph node metastases were defined using Receiver-operating characteristic curves [33].
Outcome was analyzed for Prostate-Specific Antigen (PSA) recurrence-free, cancer-specific and overall
survival defined as the intervals from surgery to the date of biochemical recurrence (PSA failure defined
as values >0.2 ng/mL), death from prostate carcinoma, and death from any cause, respectively. Patients
without event for the respective endpoints were censored at the date of last follow-up. The above
time-to-events were performed using log-rank test; p values < 0.05 were regarded as significant.
The Cox proportional hazards model was used to identify independent prognostic factors for all three
endpoints. Statistical analysis was made using SAS 9.2 (The SAS Institute, Cary, NC, USA).
5. Conclusions
Our data suggest that, firstly, increasing serum levels of neuroendocrine serum markers in
prostate cancer primarily mirror growth of a poorly differentiated metastatic tumor component and,
secondly, NED in early metastasizing, hormone-naïve prostate cancer is only weakly linked to adverse
tumor features.
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